Source: After E. Marshall, Gene therapy's growing pains, Science 269(1995):1050-1055.

Source: After E. Marshall, Gene therapy's growing pains, Science 269(1995):1050-1055.

therapies depend on an introduced gene's ability to produce a therapeutic protein. A number of different methods for transferring genes into human cells are currently under development. Commonly used vectors include genetically modified retroviruses, adenoviruses, and adeno-associated viruses (Table 18.6). One method of gene transfer is to remove cells (such as white blood cells) from a patient's body, add viruses containing recombinant genes, and then reintroduce the cells back into the patient's body. In other cases, vectors are injected directly into the body.

In spite of the growing number of clinical trials for gene therapy, significant problems remain in transferring foreign genes into human cells, getting them expressed, and limiting immune responses to the gene products and the vectors used to transfer the genes to the cells. There are also heightened concerns about safety, especially after the death in 1999 of a patient participating in a gene-therapy trial who had a fatal immune reaction after he was injected with a viral vector carrying a gene to treat his metabolic disorder. Despite this setback, gene-therapy research has moved ahead. Unequivocal results demonstrating positive benefits from gene therapy for a severe combined immunodeficiency disease and for head and neck cancer were announced in 2000.

Gene therapy conducted to date has targeted only nonre-productive, somatic cells. Correcting a genetic defect in these cells (termed somatic gene therapy) may provide positive benefits to patients but will not affect the genes of future generations. Gene therapy that alters reproductive, or germ-line, cells (termed germ-line gene therapy) is technically possible but raises a number of significant ethical issues, because it has the capacity to alter the gene pool of future generations.

0 0

Post a comment